Hydroquinone-associated ochronosis is "rare" in U.S., NDMA's Soller tells FDA at meeting.
This article was originally published in The Tan Sheet
HYDROQUINONE-ASSOCIATED OCHRONOSIS IS "RARE" IN U.S., Nonprescription Drug Manufacturers Association Director of Science & Technology Senior VP William Soller, PhD, told a July 10 OTC "feedback" meeting on the skin bleaching ingredient. Soller's presentation responded to an FDA request for additional information on exogenous ochronosis, a condition causing a deep bluish or gray discoloration of the skin, usually on the face, and its possible link to exposure to certain chemicals, including hydroquinone.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC